For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
Senate Parliamentarian Eliminates Medicaid Reform Provisions, Leaving Costs/Problems Intact
The Senate’s parliamentarian has determined that many of the Medicaid provisions in the One Big Beautiful Bill cannot be passed with simple majority vote via…
Blog
FDA can’t stomach fluoride and doesn’t want you to, either
On May 13, the Food and Drug Administration (FDA) announced that it would begin a process intended to exclude ingestible prescription fluoride products for…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
Blog
When the FTC’s anti-merger goals overshadow the prospect of saving lives
The Fifth Circuit Court of Appeals recently issued a ruling on the important case of Illumina-Grail v. Federal Trade Commission. A unanimous 3-0…
Beritbart
Unholy Alliance Between the Left and Big Pharma Threatens More Big Government Intervention in Health Care
CEI’s Joel Zinberg is cited in Breitbart on the big government intervention in healthcare: Economic experts recognize that the very foundation of a free…
City Journal
A “Coordinated Campaign”
The Covid-19 pandemic revealed a split between those who believe that the government has broad authority to control every aspect of the economy and society…
Washington Times
Cutting-edge drugs could vanish under Biden’s unprecedented move to seize patents
CEI’s Dr. Joel Zinberg is cited in the Washington Times on the Biden Administration’s move to seize patents: Dr. Joel Zinberg, a senior fellow…
National Review
Another FDA Power Grab
The comment period for the Food and Drug Administration’s latest power grab has just concluded. Roughly 20,000 comments were submitted addressing the FDA’s proposed rule which…
Comment
Comments RE: Docket No. FDA–2023–N–2177 for “Medical Devices; Laboratory Developed Tests
I am an attorney with the Competitive Enterprise Institute. The Competitive Enterprise Institute is a non-profit research and advocacy organization that focuses on regulatory policy.
